PharmaLex Belgium
PharmaLex Belgium is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Nanobiotix
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for PharmaLex Belgium?
The 2026-10-09 snapshot links PharmaLex Belgium to 3 distinct CTIS trials. Recorded services include Pharmacokinetics analysis report writing, PK data analysis and modelling, Statistical analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for PharmaLex Belgium?
The most frequently recorded therapeutic areas are Immunology, Neurology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to PharmaLex Belgium conducted?
The linked trials record locations in 7 countries, including Germany, Bulgaria, Czechia, Poland, Romania. These are trial locations, not confirmed office locations or countries where PharmaLex Belgium delivered services.
What can this page tell me about PharmaLex Belgium's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under PharmaLex Belgium. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- PharmaLex Belgium